A total of 32 patients suffering from acute myeloid leukaemia were initially treated with daunorubicin and cytosine arabinoside, and eight who achieved full remission were given a brief cytoreduction course of cyclophosphamide and thioguanine. Of these eight patients seven were then actively immunized with 10' irradiated allogeneic acute myeloid leukaemia cells and B.C.G. at weekly intervals. Six of these patients have survived in apparent good health for more than one year. Bone marrow changes suggestive of relapse were used as an indication for further short courses of chemotherapy, and except on single occasions in two different patients clinical relapse has been prevented. The average duration of first (bone marrow) remission appears to be comparable with the best achieved in trials using regular chemotherapy for maintenance, though criteria for determining relapse may be different. The rate of reinduction of remissions (bone marrow) in this series was high, with a subsequent increase in overall survival time. Possible explanations for the high rate of reinduction include, firstly, the effects of active immunization with specific leukaemia antigen; secondly, non-specific adjuvant effect; thirdly, avoidance of drug resistance; and, fourthly, early diagnosis of relapse by frequent bone marrow examinations.
Introduction
Human leukaemia cells may possess surface antigens capable of provoking an immune response in the host (Harris, 1973) . Attempts have been made to increase this response both in experimental animals and more recently in man by various forms of active specific and non-specific immunization. In human acute leukaemia encouraging results are being obtained using a combination of active immunization with irradiated allogeneic cells and B.C.G. with or without Corynebacterium parvum. Such immunotherapy is administered only after remission has been induced and the leukaemic cell mass greatly reduced by means of chemotherapy. Using such treatment Mathe et al. (1972) claim that about 50% of patients with acute lymphoblastic leukaemia achieve a first remission of 12 months duration. Similarly Crowther et al. (1973) and Powles et al. (1973) , treating patients with acute myeloid leukaemia, have reported that intermittent combination chemotherapy plus immunotherapy produces longer remissions than the same chemotherapy given alone.
In this preliminary report we describe a protocol in which immunotherapy is used alone during remission. Chemotherapy is reserved for initial remission induction and cytoreduction and for treating patients in whom routine bone marrow examination suggests that clinical relapse is imminent. In the small group of patients with acute myeloid leukaemia who were treated in this way normal bone marrow appearances were reinduced with remarkable ease and second, third, and fourth "remissions" were obtained with excellent overall survival and sense of wellbeing. 
Patients and
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Remissibn induction was attempted with daunorubicin and cytosine arabinoside administered as described by Crowther et al. (1973) (Buckner et al., 1969) . The cells were stored at approximately -179°C in a Union Carbide g is-phase liquid nitrogen container after programmed freezing in a G.V. Planer low-temperature refrigeration unit. Before injection leukaemia cells were thawed rapidly, washed twice in Ringer's solution, and placed on ice. They were then subjected to irradiation at 10,000 rads (3,000 rads/min) using an A.E.I. 4-MV linear accelerator. The irradiation was performed at 22°C, after which the cells were again placed on ice until injected. Leukaemia cells were injected intradermally and subcutaneously into three limbs within half an hour of thawing. B.C.G. (Glaxo) was administered by the multiple-puncture technique using a 20-needle Heaf gun fired twice into the fourth limb.
Complete remission was judged to have occurred when the marrow aspirate, usually obtained from the sternum, showed fewer than 5% blasts and promyelocytes with recovery of other normal marrow elements, a rising peripheral blood platelet and neutrophil count, a steady or rising haemoglobin level not maintained by transfusions, and absence of lymphadenopathy or splenomegaly. The stricter criteria of the leukaemia group B (Ellison et al., 1968) , including absence of clinical symptoms, a peripheral neutrophil count of above 1,500/mm3, and a haemoglobin of at least 12 g/100 ml (11 g/100 ml in women), could be used only retrospectively, after the start of immunotherapy, as cytoreduction chemotherapy was initiated before full recovery of haematological values. All patients receiving immunotherapy eventually fulfilled these criteria.
A marrow aspirate was obtained routinely at monthly intervals during immunotherapy, and more often if the patient developed clinical symptoms or changes in the peripheral blood counts suggestive of relapse. In most cases relapse was diagnosed on the basis of an increased level of abnormal blasts above 5% on bone marrow examination. When the blast count had risen only slightly, say 5-10%, without any changes in the peripheral blood counts or clinical deterioration, the bone marrow examination was repeated two weeks later. If there was any further increase in the number of abnormal blast cells chemotherapy was reinstituted. Reinduction chemotherapy was identical with that used for initial remission induction, but no cytoreduction therapy was given. Patients achieving a further remission again received immunotherapy with leukaemia cells from a different donor plus B.C.G.
Results
Of the 32 patients 8 (25%) achieved complete remission and 7 subsequently received immunotherapy (see fig.) (Wiernik, et al., 1970; Crowther et al., 1973) , though in our hands the reinduction rate was previously not more than 12% (Bailey et al., 1971) . Moreover, third and fourth remissions are extremely rare. It is not clear whether the high reinduction rate in our patients treated with immunotherapy was a positive result of immunotherapy or attributable to the absence of maintenance chemotherapy and the avoidance of drug resistance. The latter explanation seems perhaps less likely in view of the fact that only one out of five patients who went into remission in the fourth and fifth M.R.C. trials on acute myeloid leukaemia and who for various reasons received no further treatment achieved a remission after subsequent relapse (Galton, 1973) . Haddow and Alexander (1964) reported that the effectiveness of a single dose of 2,000 r of x-rays in retarding the growth of primary rat fibrosarcoma can be enhanced by an autograft of the tumour. One patient with acute lymphoblastic leukaemia treated with immunotherapy at the Royal Manchester Children's Hospital, Pendlebury (Morris Jones, 1973) , was put back on to the same maintenance chemotherapy as he had received before immunotherapy. The same dose of drugs produced marked marrow hypoplasia, suggesting an increased sensitivity of the normal marrow elements to chemotherapy.
The ease of reinduction might also be attributed to the relatively early diagnosis of relapse in our series. In most patients relapse was based on the results of bone marrow examination which we performed monthly, and only occasionally was there any change in the peripheral blood counts. Only the one patient who eventually died and a further patient after his second relapse showed clinical signs of relapse.
Centres where bone marrow examination is performed less often and which depend more on clinical and peripheral blood evidence of relapse may find greater difficulty in reinducing a remission. Though the apparent duration of first remission may be greater overall survival would then be shorter.
We are deeply indebted to our many colleagues in the depart- ADDENDUM.-The latest data on patients receivg immunotherapy are as follows. Case 1 relapsed at 95 weeks and has since achieved a fifth remission (current overall survival 107 weeks). Case 14 died without achieving a further remission after a total of 72 weeks. Cases 19 and 29 are still in their first remission (duration 73 and 55 weeks respectively; current overall survival 78 and 60 weeks respectively). Case 21 remains in his second remission (duration 42 weeks; current overall survival 76 weeks). Case 26 relapsed for a second time at 64 weeks but has achieved a third remission (current overall survival 71 weeks).
Introduction
It is now widely accepted that maternal smoking in pregnancy is associated with both a reduction in birth weight and an increase in perinatal mortality (Butler et al., 1972; British Medical_Journal, 1973) . Though there is still some dispute about the mechanism of the association the evidence from human and animal studies suggests that it is the smoking rather than the type of woman who smokes which is responsible (British Medical Journal, 1973) .
The long-term effects of smoking in pregnancy on the surviving child are less well documented. Hardy and Mellits (1972) found very few significant differences in a number of body measurements and intellectual functions up to the age of 7 years between children of smokers and non-smokers. On the other hand, by using data from the National Child Development
